The largest drug
discovery company
in the CEE region

More

Your integrated drug
discovery partner of choice

More

Developing breakthrough
therapies in oncology

More

Delivering comprehensive
research solutions to biotech
and pharma

More

News See all

pim1_4enx_fig05_low_res_niebieskie

Selvita researchers publish MNK inhibitors review in Current Medicinal…

Kraków, Poland – 13 February 2017 - MNK1 and MNK2 are MAP kinase-interacting serine/threonine kinases, which are activated by RAS...
More
KR151014AB_001

Selvita announces a ten-year laboratory infrastructure development plan

Krakow, Poland – 22 September 2016 - Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, has...
More
????????????????????????????????????

Selvita presenting at the Building Central European – American…

Kraków, Poland  - 23 January 2017 - Selvita will participate and present at the upcoming "Building Central European – American Bridges...
More
bts17_eweb_team_banner_1200x600-1024x512

Selvita to present at Biotech Showcase 2017 in San…

Krakow, Poland - 16 December 2016 - Selvita (WSE:SLV), a drug discovery company, announced today that its Chief Scientific Officer,...
More
boston-photo1

Selvita will be exhibiting at the 5th MassBio CRO/CMO…

Krakow, Poland - December 1, 2016 - Selvita will be exhibiting at the 5th Annual  MassBio CRO/CMO Symposium at the...
More

About Selvita

Selvita has two primary focus areas:

– to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services and

– as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.

More

Drug Discovery Services

Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries.

We offer drug discovery support at every stage of the early discovery phase up to the preclinical research phase.

More

REsearch and Development

Selvita is actively engaged in the discovery and development of breakthrough medicines primarily in the area of oncology. 

Our most advanced project is about to enter the clinic in Q4 2016.

More

Investor Relations SLV -1.47 (-4.39%)

Share price 2017-02-17 17:00:00

32.03 PLN More

Careers

We are a multicultural and a multinational company employing professionals from all over the world.

Find out who we’re courrently looking for and what we can offer our employees.

More